Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
Abstract While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose psoriasis fails to respond to one biologic to swi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2020-06-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-020-00411-w |
| _version_ | 1827316169772630016 |
|---|---|
| author | Alan Menter April Armstrong Abby Van Voorhees Clive Liu Abby Jacobson |
| author_facet | Alan Menter April Armstrong Abby Van Voorhees Clive Liu Abby Jacobson |
| author_sort | Alan Menter |
| collection | DOAJ |
| description | Abstract While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose psoriasis fails to respond to one biologic to switch to a different biologic therapy, in particular one with a different mechanism of action. However, it remains unclear how prior biologic exposure or lack of response affects the efficacy and safety of subsequent biologics in patients with moderate-to-severe psoriasis. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has previously been shown to be efficacious in treating moderate-to-severe psoriasis in three large phase 3 trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3). In this review, we summarize the efficacy and safety of brodalumab in patients with moderate-to-severe psoriasis and a history of biologic exposure. Further, we describe improvements in skin clearance and quality of life measures as well as safety in patients who had inadequate response to ustekinumab and who were rescued with brodalumab therapy. Lastly, we discuss improvements in skin clearance following rescue with brodalumab in patients whose disease failed to respond to secukinumab and ixekizumab. The findings of our review suggest that brodalumab is a safe and efficacious treatment regardless of past biologic use or lack of response to prior biologic therapy. |
| first_indexed | 2024-04-24T23:10:18Z |
| format | Article |
| id | doaj.art-4612677df7ab489a87d73d7e4fd40a9c |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-04-24T23:10:18Z |
| publishDate | 2020-06-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-4612677df7ab489a87d73d7e4fd40a9c2024-03-17T12:15:26ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722020-06-0110461562110.1007/s13555-020-00411-wBrodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to BiologicsAlan Menter0April Armstrong1Abby Van Voorhees2Clive Liu3Abby Jacobson4Baylor Scott & WhiteUniversity of Southern CaliforniaEastern Virginia Medical SchoolBellevue DermatologyOrtho Dermatologics (a division of Bausch Health US, LLC)Abstract While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose psoriasis fails to respond to one biologic to switch to a different biologic therapy, in particular one with a different mechanism of action. However, it remains unclear how prior biologic exposure or lack of response affects the efficacy and safety of subsequent biologics in patients with moderate-to-severe psoriasis. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has previously been shown to be efficacious in treating moderate-to-severe psoriasis in three large phase 3 trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3). In this review, we summarize the efficacy and safety of brodalumab in patients with moderate-to-severe psoriasis and a history of biologic exposure. Further, we describe improvements in skin clearance and quality of life measures as well as safety in patients who had inadequate response to ustekinumab and who were rescued with brodalumab therapy. Lastly, we discuss improvements in skin clearance following rescue with brodalumab in patients whose disease failed to respond to secukinumab and ixekizumab. The findings of our review suggest that brodalumab is a safe and efficacious treatment regardless of past biologic use or lack of response to prior biologic therapy.https://doi.org/10.1007/s13555-020-00411-wInterleukin-17 receptorLoss of responsePsoriasis area and severity indexStatic physician’s global assessment |
| spellingShingle | Alan Menter April Armstrong Abby Van Voorhees Clive Liu Abby Jacobson Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics Dermatology and Therapy Interleukin-17 receptor Loss of response Psoriasis area and severity index Static physician’s global assessment |
| title | Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics |
| title_full | Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics |
| title_fullStr | Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics |
| title_full_unstemmed | Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics |
| title_short | Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics |
| title_sort | brodalumab to the rescue efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics |
| topic | Interleukin-17 receptor Loss of response Psoriasis area and severity index Static physician’s global assessment |
| url | https://doi.org/10.1007/s13555-020-00411-w |
| work_keys_str_mv | AT alanmenter brodalumabtotherescueefficacyandsafetyofbrodalumabinpatientswithpsoriasisandpriorexposureorinadequateresponsetobiologics AT aprilarmstrong brodalumabtotherescueefficacyandsafetyofbrodalumabinpatientswithpsoriasisandpriorexposureorinadequateresponsetobiologics AT abbyvanvoorhees brodalumabtotherescueefficacyandsafetyofbrodalumabinpatientswithpsoriasisandpriorexposureorinadequateresponsetobiologics AT cliveliu brodalumabtotherescueefficacyandsafetyofbrodalumabinpatientswithpsoriasisandpriorexposureorinadequateresponsetobiologics AT abbyjacobson brodalumabtotherescueefficacyandsafetyofbrodalumabinpatientswithpsoriasisandpriorexposureorinadequateresponsetobiologics |